Vice President Kamala Harris is trumpeting lower prescription drug costs for seniors as a campaign hallmark, but will the savings materialize?

That depends, brokers say.

The climate and health care law called the Inflation Reduction Act, trumpeted by the Biden administration as a signature achievement, radically redesigned Medicare’s drug benefit for 2025.

Ken Brandy, principal at KMB Insurance Services in Imperial, calls the Medicare prescription drug changes starting in January the biggest he’s seen in a 20-year career in health insurance.

Advertise with us

“It’s going to hit the fan,” he said. “It’s already hitting the fan.”

Open enrollment for Medicare Advantage and supplemental prescription plans for seniors with traditional Medicare continues through Dec. 7 when seniors can change coverage for 2025.

Medicare’s Part D drug benefit, which was enacted in 2003, serves about 53 million people age 65 and older or people who have disabilities.

The administration estimates that about 18.7 million people will see lower drug costs next year — 76,000 seniors in Pennsylvania alone — and save about $7.4 billion, thanks to the new $2,000 cap on out-of-pocket spending on prescriptions and other program changes. That means about 36% of U.S. seniors will pay less at the drugstore next year than in 2024.

“The prices we’ve negotiated bring foundational and critical change to the Medicare program,” said Andrea Palm, deputy secretary, U.S. Health & Human Services. “It’s such a change from previous law. It’s historic.”

Advertise with us

Which is a very big deal for people like Diana DiVito.

For nine years, the North Strabane resident has been treated for chronic lymphocytic leukemia, which is among the most common forms of the blood cancer. Every year, her prescription costs rose by about $1,000, she said, and she has paid out-of-pocket as much as $12,000 a year for the cancer-killing drug ibrutinib, which is sold as Imbruvica.

“It’s a very expensive drug, but it kept me alive,” said Ms. DiVito, 83, who retired from an affordable housing development organization in Station Square.

Starting in January, her out-of-pocket prescription expense for the leukemia drug will be capped at $2,000. Imbruvka was among the drugs that the U.S. government negotiated lower prices with pharmaceutical companies.

After beneficiaries spend $2,000 on deductibles and copays, the rest of their Part D drugs are free for the rest of the year.

Advertise with us

“You’re going to pay a little more upfront, but overall, the cap is going to help a lot of people,” Mr. Brandy said. “It’s the right direction to go.”

But not everyone will see lower costs at the prescription counter, said Rob Sedney, independent insurance broker at Centurion Senior Services in Scott. He has been on the phone nonstop with clients, encouraging them to compare Medicare Advantage and supplemental plan prescription coverage to avoid unpleasant surprises come Jan. 1.

“Where it’s going to hurt is for people who don’t take expensive drugs,” Mr. Sedney said. “Only a fraction of the overall population will save money. It’s not like everybody’s saving money.”

The real savings will be for seniors who take expensive brand name drugs, which are often listed on the third and higher drug formulary tiers.

A senior who is only taking generic prescription drugs may not see much of a difference next year, Mr. Brandy added.

Advertise with us

Aetna CVS Health and Highmark, two of Western Pennsylvania’s biggest Medicare Advantage insurers, are shifting to a percentage prescription co-pay next year from a flat copay. Consumers could wind up paying more, depending on what kind of drugs they take and whether they’re eligible for Medicare’s Extra Help prescription program.

An analysis by San Francisco-based nonprofit KFF found that “many insurers are increasing premiums” and that large insurers, including UnitedHealthcare and Aetna, reduced the number of plans they are offering for 2025.

Aetna’s popular Part D SilverScript SmartSaver plan will no longer be sold nationwide in 2025. Enrollees will be shifted into Aetna’s SilverScript Choice plan, unless they opt out, which will bump monthly premiums to $53.60 from $18.60, a $35 increase, according to a KFF analysis.

Mr. Brandy attributed the price increases to insurers recouping some costs of the increasingly rich Medicare Advantage plan benefits of recent years.

“The plans were getting so good,” he said, “they had to pull back a little bit.”

Advertise with us

Health insurance coverage isn’t the only way seniors will be impacted by the Inflation Reduction Act changes, the HHS’ Ms. Palm said.

This year, Medicare recipients are eligible for free vaccines, including ones for RSV, shingles and hepatitis A and B. Insulin is also capped at $35 for a month’s supply and the law will limit price hikes to the consumer price inflation rate, which was 3.4% in 2023.

If drug prices rise faster than inflation, pharmaceutical companies have to pay Medicare the difference.

Subsidies for about 17 million low-income people in Medicare drug plans expanded this year, increasing the subsidy for prescription costs.

Ms. Palm said all seniors will benefit from the government’s new ability to negotiate drug prices with pharmaceutical companies.

Advertise with us

For-profit Medicare Advantage and Part D plan sponsors can drop covered drugs and eliminate pharmacies and other services from the provider networks that beneficiaries must use, driving up costs and making comparative shopping especially important this year, brokers say.

Seniors can get free, unbiased help in choosing drug coverage by contacting Pennsylvania Medicare Education and Decision Insight at https://tinyurl.com/t9bynm5y or 1-800-783-7067.